Wave Neuroscience

What Wave Neuroscience does

Wave Neuroscience is a private, Newport Beach-based neurotechnology company founded in 2019 that has developed MeRT (Magnetic e-Resonance Therapy), a personalized neuromodulation platform combining rapid quantitative EEG assessments with customized Transcranial Magnetic Stimulation (TMS). The system uses proprietary algorithms to analyze EEG-derived brain activity biomarkers and generate individualized treatment parameters, supported by a database of 60,000+ brainwave recordings that underpins the company's Braincare analysis platform. In June 2026, MeRT became the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for the treatment of PTSD in adults, following an FDA Breakthrough Device Designation awarded in December 2024 and supported by a 158-patient double-blinded randomized controlled multisite trial conducted with Texas A&M Health.

The company operates a B2B distribution model, licensing MeRT technology, protocols, and training to a network of independently owned and operated clinics rather than selling directly to consumers. Its provider footprint spans 60+ US clinic locations across 23 states plus international providers in 10+ countries, augmented by a channel partnership with Restore Hyper Wellness (225+ studios across 40 states) that extends the consumer-facing Braincare offering into the wellness and performance segment. Key customer segments include military veterans and first responders (the primary clinical segment), adults with neuropsychiatric conditions, performance optimization seekers (e.g., professional athletes), and pediatric neurodevelopmental research (autism spectrum disorder). The company also holds assets from the 2020 acquisition of NeoSync, including the NEST system designed for eventual home-use, signaling a longer-term product-line expansion beyond clinic-delivered TMS.

Name

Wave Neuroscience

Legal name

Wave Neuroscience Inc.

Website

https://waveneuro.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Wave Neuroscience is a private neuromodulation company that develops MeRT, an FDA-cleared EEG-guided transcranial magnetic stimulation system for PTSD and related neurological conditions, distributed through a provider network of 60+ US clinics across 23 states and 10+ international markets.

Ownership category

akta.pro rank

Product category

Personalized Neuromodulation Technology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Personalized neuromodulation
• EEG-guided TMS therapy
• Brainwave analysis platform
• Transcranial magnetic stimulation
• PTSD treatment technology

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. MeRT Treatment Services: Revenue generated through independent clinics and providers offering MeRT treatments to patients. The company provides technology and protocols to provider network.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Wave Neuroscience develops the MeRT® (Magnetic e-Resonance Therapy) System, which combines rapid quantitative EEG (qEEG) assessments with personalized Transcranial Magnetic Stimulation (TMS) protocols guided by proprietary algorithms. The Braincare™ cloud platform processes brainwave recordings against a database of 60,000+ recordings to generate individualized treatment parameters. The company licenses these technologies and protocols to a global network of independent clinics and institutional partners rather than treating patients directly.

Product overview

Wave Neuroscience offers a unified SaaS platform centered on MeRT® (Magnetic e-Resonance Therapy), a patented personalized neuromodulation system. The platform consists of MeRT® as the core treatment product and Braincare™ as the assessment and analysis platform. Braincare™ leverages advanced EEG neuroimaging to evaluate brain function and generate personalized treatment protocols, which MeRT® then delivers through customized Transcranial Magnetic Stimulation. The system uses AI-driven analysis of brainwave data to individualize treatment frequencies, representing a shift from traditional one-size-fits-all neuromodulation approaches.

Differentiator

Problem solved

Functional benefit

Brands

• MeRT: Magnetic e-Resonance Therapy - FDA-cleared personalized neuromodulation technology combining EEG assessments with transcranial magnetic stimulation
• Braincare

Products and services

• MeRT® (Magnetic e-Resonance Therapy) FDA-cleared personalized neuromodulation system that combines rapid quantitative EEG (qEEG) assessments with electrocardiogram (EKG) to analyze brain network function and guide individualized Transcranial Magnetic Stimulation (TMS) protocols using proprietary AI algorithms; licensed to independent clinics for treating PTSD, TBI, depression, and other neurological conditions.
• Braincare™ Cloud-based analysis platform that processes EEG-derived brainwave recordings against a proprietary database of 60,000+ recordings to generate digital brain images and personalized treatment protocols with age/gender-matched comparisons, delivered as a SaaS to provider clinics and partner wellness studios.

Quantifiable outcome

• 63% PTSD symptom improvement (PCL-5 scale) with eTMS, more than 4 times better than standard TMS at 31%
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Texas A&M Health Institute of Biosciences and TechnologycoreStrategic or Co-development Partner · 11 June 2026Partnership for double-blinded randomized controlled multisite clinical trial supporting FDA clearance for MeRT system for PTSD. Trial demonstrated significant and clinically meaningful reductions in PTSD symptom severity with 158 patients enrolled.
• Virginia TechcoreStrategic or Co-development Partner · 10 June 2025Clinical trial sponsor for eTMS (MeRT) for Veterans and First Responders With PTSD. Trial currently recruiting with estimated enrollment of 20 participants.
• Ohio Department of Mental Health and Addiction Services (OMAS)coreStrategic or Co-development Partner · 26 February 2025Ohio state program implementing eTMS for veterans and first responders. Over 800 individuals treated with outcomes tracked through real-time data dashboard. Senator Frank Hoagland advocacy for legislative support.
• Wright State UniversitycoreStrategic or Co-development Partner · 6 November 2023$160,000 funding for stage 1 clinical trial on eTMS safety for PTSD treatment in military veterans and first responders. Dr. Matt Sherwood leading research with team of graduate students.
• Restore Hyper WellnessmajorChannel Partner/ Reseller/ Distributor · 21 September 2023Restore Hyper Wellness, with 225+ studios in 40 states, partnered with Wave Neuro to offer Braincare technology. Winner of Restore's 2023 Technology Award recognizing innovative technology leader.
• SOCOM and Department of DefensecoreStrategic or Co-development Partner · 4 April 2022MeRT-TBI-005 clinical trial evaluating safety and efficacy of MeRT for Persistent Post-Concussive Symptoms in service members.
• NeoSynccoreOEM/ Whitelabel/ Licensing Partner · 26 February 2020Wave Neuroscience acquired NeoSync's technology assets including NEST system. NEST is designed for eventual home-use, expanding accessibility to neuromodulation treatment.
• SOC-F and TCS (Special Operations Care Fund and Tomahawk Charitable Solutions)coreGTM or Marketing Partner · 4 September 2019Collaboration to facilitate treatment by BTC San Diego of Special Operations Forces veterans struggling with lack of focus, chronic sleep disruption, and cognitive fog. 18-month program.
• Global SOF FoundationcoreGTM or Marketing Partner · 16 January 2019Foundation championed Wave Neuro's technology for treating SOF veterans with TBI and PTSD, resulting in Congressional Bill H.R. 1162 'No Hero Left Untreated' for VA pilot program.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Neuronetics: Neuronetics manufactures NeuroStar, the leading FDA-cleared TMS device primarily indicated for depression. Direct competitor in TMS-based neuromodulation with overlapping physician and clinic channels in the U.S.
• Brainsway: Brainsway develops deep TMS systems (H-coil) with FDA clearances for depression, OCD, and smoking cessation. Direct competitor in non-invasive TMS neuromodulation, especially in psychiatric indications.
• Magstim: Magstim manufactures TMS stimulators and coils used widely in research and clinical practice. Direct competitor in the TMS device market, particularly in neurology and psychiatry research settings.
• MagVenture: MagVenture produces FDA-cleared TMS systems for depression and clinical research applications. Direct peer offering TMS equipment to similar physician and clinic customers.
• Soterix Medical: Soterix Medical develops non-invasive brain stimulation platforms including TMS and tDCS for research and clinical use. Direct peer in the non-invasive neuromodulation device market.
• Neurosoft: Neurosoft manufactures TMS devices (e.g., Neuro-MS) for depression and neurological disorders, primarily serving European and international markets. Direct peer in non-invasive TMS hardware with comparable indications.
• Fisher Wallace: Fisher Wallace markets wearable cranial electrotherapy stimulators for depression, anxiety, and insomnia. Direct peer in non-invasive, at-home brain stimulation for psychiatric indications.

Emerging players

• Alto Neuroscience: Alto Neuroscience develops biomarker-guided therapeutics for depression and other psychiatric conditions. Emerging peer operating in the same personalized-mental-health category with overlapping patient populations.
• Big Health: Big Health builds digital therapeutics (Sleepio, Daylight) for insomnia and anxiety, often comorbid with PTSD/depression. Emerging peer addressing the same mental-health patient base via non-pharmacological approaches.
• Apollo Neuroscience: Apollo Neuroscience produces a wearable that delivers low-frequency vibration to improve sleep, focus, and stress resilience. Emerging peer in the consumer-facing, non-invasive brain stimulation category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wave-neuroscience

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wave Neuroscience